

## ORIGINAL ARTICLE

# *In vitro* and *in vivo* activity of a hypotoxic copper(I) complex against dermatropic *Leishmania* species

Ana Flávia da Silva CHAGAS<sup>1,2,\*</sup>, Marina PORCHIA<sup>2</sup>, Thaís Pinto NASCIMENTO<sup>1</sup>, Carolina Nunes Souza CORREA<sup>1</sup>, Anny Maíza Vargas BRASIL<sup>1,2</sup>, Antonia Maria Ramos FRANCO<sup>1</sup>

<sup>1</sup> Universidade Federal do Amazonas, Programa de Pós-Graduação em Inovação Farmacêutica, Manaus, 69067-005, Amazonas, Brazil

<sup>2</sup> Instituto Nacional de Pesquisas da Amazônia, Laboratório de Leishmaniose e Doença de Chagas, Manaus, 69067-375, Amazonas, Brazil

<sup>3</sup> Istituto di Chimica della Materia Condensata e di Tecnologie per l'Energetica, Consiglio Nazionale delle Ricerche, Padova, 4-35127, Italy

\* Corresponding author: [chagas.afs@gmail.com](mailto:chagas.afs@gmail.com); <https://orcid.org/0000-0002-6677-9833>

## ABSTRACT

Cutaneous leishmaniasis is a disease caused by protozoa of the genus *Leishmania* and, currently, the treatment of first choice is meglumine antimoniate. However, due to its limited effectiveness and high toxicity, it is necessary to seek new active principles for leishmaniasis treatment. Metal complexes are gaining importance due to their effectiveness and low toxicity. In this context, the present study aimed to evaluate the *in vitro* and *in vivo* antileishmanial activity of the hypotoxic copper(I) complex [HB(pz)<sub>3</sub>]Cu(PCN). Four dermatropic species of *Leishmania* were tested with the metal complex and its effectiveness was determined through parasitic viability and infectivity rate, and cytotoxicity was determined using a redox dye (resazurin). For the *in vivo* tests, hamsters were infected and the lesions treated with a formulated ointment containing the complex, the effectiveness of which was assessed by measuring the diameter of the inoculum/snout location and determining the parasitic load. The results demonstrated moderate toxicity in murine macrophages and human monocytes and better efficacy in *Leishmania (V.) braziliensis* when compared to the other species tested, with a 50% reduction in the viability of promastigote and amastigote forms (*in vitro*). General data from daily topical treatment for up to 30 days showed low efficacy for reducing lesions, and no clinical and parasitological cure was observed in the experimental animals. Thus, the [HB(pz)<sub>3</sub>]Cu(PCN) complex proved to be promising in *in vitro* studies against *L. (V.) braziliensis*, and should be further tested in new formulations and new experimental treatment schemes.

**KEYWORDS:** leishmaniasis, treatment, metallic complex, antileishmanial activity

## Atividade *in vitro* e *in vivo* de um complexo de cobre(I) hipotóxico contra espécies dermatrópicas de *Leishmania*

### RESUMO

A leishmaniose cutânea é uma doença causada por protozoários do gênero *Leishmania* e, atualmente, o tratamento de primeira escolha é o antimoniato de meglumina. Porém, devido à sua eficácia limitada e alta toxicidade, é necessário buscar novos princípios ativos para o tratamento da leishmaniose. Os complexos metálicos vêm ganhando importância devido à sua eficácia e baixa toxicidade. Nesse contexto, o presente estudo teve como objetivo avaliar a atividade leishmanicida *in vitro* e *in vivo* do complexo hipotóxico de cobre(I) [HB(pz)<sub>3</sub>]Cu(PCN). Quatro espécies dermatrópicas de *Leishmania* foram testadas com o complexo metálico e sua eficácia foi determinada através da viabilidade parasitária e taxa de infectividade, e a citotoxicidade foi determinada com um corante redox (resazurina). Para os testes *in vivo*, hamsters foram infectados e as lesões foram tratadas com uma pomada formulada contendo o complexo. A eficácia foi avaliada medindo o diâmetro do inóculo/focinho e determinando a carga parasitária. Os resultados demonstraram toxicidade moderada em macrófagos murinos e monócitos humanos e melhor eficácia em *Leishmania (V.) braziliensis* quando comparada às demais espécies testadas, com redução de 50% na viabilidade das formas promastigotas e amastigotas (*in vitro*). Os dados gerais do tratamento tópico diário por até 30 dias mostraram baixa eficácia na redução das lesões, e nenhuma cura clínica e parasitológica foi observada nos animais experimentais. Portanto, o complexo [HB(pz)<sub>3</sub>]Cu(PCN) mostrou-se promissor em estudos *in vitro* contra *L. (V.) braziliensis*, devendo ser empregado em novas formulações e novos esquemas de tratamento experimental.

**PALAVRAS-CHAVE:** leishmaniose, tratamento, complexo metálico, atividade antileishmania

**CITE AS:** Chagas, A.F.S.; Porchia, M.; Nascimento, T.P.; Correa, C.N.S.; Brasil, A.M.V.; Franco, A.M.R. 2021. *In vitro* and *in vivo* activity of a hypotoxic copper(I) complex against dermatropic *Leishmania* species. *Acta Amazonica* 51: 260-269.

## INTRODUCTION

Cutaneous leishmaniasis (CL) is a neglected disease and endemic in more than 92 countries, with over 90% of cases occurring in the Americas (WHO 2021). Transmission is vectorial, and its etiological agents are the protozoans of the genus *Leishmania* (Blanco 2017). Currently, at least 20 species are known to be pathogenic to man and, among them, a total of seven dermatropic species are found in Brazil. *Leishmania (Viannia) guyanensis*, *L. (V.) braziliensis* and *L. (Leishmania) amazonensis* are highlighted in Brazil due to their wide distribution and the induction of different clinical manifestations (Teles *et al.* 2016).

In the treatment of CL, pentavalent antimonials are most commonly employed, and pentamidine and amphotericin B are the drugs of second choice. Considering that these drugs have low efficacy due to parasitic diversity and resistance, high toxicity, and require a long and painful treatment, the search for new active principles with more effective action is warranted (Bastos *et al.* 2016; Brasil 2017).

In this context, metal complexes are prominent candidates, as they have unique properties, such as the ability to bypass resistance mechanisms and the possibility of being used in multi-target molecule design (compounds that can reach the target organism by at least two independent mechanisms) (Ong *et al.* 2019). Transition metals have peculiar characteristics that favor performance in biological functions, and copper (Cu) is a biologically active transition metal (Krupanidhi *et al.* 2008).

Copper(I/II) compounds have been widely evaluated for their anti-tumor properties (e.g. Tisato *et al.* 2016; Hussain *et al.* 2019; Porchia *et al.* 2020), and have also been proposed for other therapeutic purposes, e.g. as antimalarial agents (Tapanelli *et al.* 2017). Several studies have investigated the activity of copper complexes in different oxidation states, and Cu(II) complexes have shown promising results *in vitro* against *Leishmania* spp. (Maffei *et al.* 2009; Portas *et al.* 2012; Arndt *et al.* 2017; Méndez-Arriaga *et al.* 2018). Copper is physiologically internalized by eukaryotic cells as copper(I), however, only Navarro *et al.* (2003) and Saeed *et al.* (2018) have shown the activity of copper(I) complex against promastigote forms.

The copper(I) complex [HB(pz)<sub>3</sub>]Cu(PCN) presented *in vitro* and *in vivo* cytotoxic activity in cancer cells (Gandin *et al.* 2014). Considering that anticancer drugs can exert antileishmanial activity (Keighobadi *et al.* 2018), the aim of this study was to evaluate the *in vitro* and *in vivo* antileishmanial activity of the [HB(pz)<sub>3</sub>]Cu(PCN) complex in *Leishmania* spp., and the effects of cytotoxicity on murine peritoneal macrophages and human monocytes.

## MATERIALS AND METHODS

### Substance

The target molecule in this study was the hypotoxic copper(I) [HB(pz)<sub>3</sub>]Cu(PCN) complex, where PCN = triscyanomethylphosphine and HBPz<sub>3</sub> = trispyrazolylborate anion. This compound was synthesized and purified as previously described by Gandin *et al.* (2014), and the meglumine antimoniate (Glucantime<sup>®</sup>; Sanofi-Aventis, São Paulo, Brazil) was used as a drug of standard choice (Brasil 2017).

### Parasites

The strains used in this study were *Leishmania (Leishmania) amazonensis* (IFLA/BR/1967/PH8), *Leishmania (Viannia) guyanensis* (MHOM/BR/1975/M4147), *Leishmania (Viannia) braziliensis* (MHOM/BR/1975/2904) and *Leishmania (Viannia) naiffi* (MDAS/BR/1979/M5533), obtained from the Roswell Park Memorial Institute (RPMI 1640 - Sigma Chemical Co. St. Louis, USA), supplemented with 10% inactivated fetal bovine serum - FBSi (LGC Biotecnologia, São Paulo, Brazil) and 50 µg mL<sup>-1</sup> gentamicin (Novafarma, Brazil) - complete RPMI medium, incubated at 25 °C and kept in the Laboratory of Leishmaniasis and Chagas Disease at Instituto Nacional de Pesquisas da Amazônia (INPA), Manaus, Brazil.

### *In vitro* biological assay

Murine peritoneal macrophages and human monocytes (primary culture/individual assays) were grown in 96-well plates (10<sup>5</sup> cells mL<sup>-1</sup>) in complete RPMI medium, in an incubator containing 5% CO<sub>2</sub> (Form Series II Water Jacket CO<sub>2</sub> Incubator, Thermo Scientific, USA) at 37 °C, for 24 h. The cells were treated with different concentrations of the copper(I) complex (0.16, 0.08, 0.04, 0.02 and 0.01 mM) or Glucantime<sup>®</sup> (33.00, 16.50, 8.25, 4.12 and 2.06 mM). Wells without cells were kept blank and wells with cells though without treatment were maintained as controls. Cell viability was assessed using resazurin sodium salt (Sigma Aldrich<sup>™</sup>, USA) during 24, 48 and 72 h with the addition of 10 µL of stock solution of resazurin sodium salt (4 mg mL<sup>-1</sup> in phosphate buffered saline) in each well and the plates incubated again for another 12 h at 37 °C. The absorbance was read on a spectrophotometer (Elx800<sup>™</sup>, BIO-TEK<sup>™</sup>, USA) at a wavelength of 590 nm. The data were normalized according to the following formula: % of survival = Abs. Sample-Abs. blank/bs. control-Abs. blank × 100 (Nascimento *et al.* 2019).

### Biological assays in promastigote forms

Promastigotes were grown in 96-well plates (2x10<sup>6</sup> promastigotes mL<sup>-1</sup>) in complete RPMI medium and treated over 24, 48 and 72 h with different concentrations of the copper(I) complex (0.16, 0.08, 0.04, 0.02 and 0.01 mM) or Glucantime<sup>®</sup> (33.00, 16.50, 8.25, 4.12 and 2.06 mM).

Wells with untreated promastigotes were maintained as controls. Biological activity was determined by quantifying viable promastigotes in a hemocytometer, using an optical microscope (Eclipse E200, Nikon, Japan) with 400x magnification. The data were expressed as half of the maximum inhibitory concentration ( $IC_{50}$ ) and the selectivity index (SI) was calculated from the ratio between cytotoxicity to human monocytes ( $CC_{50}$ ) and the activity against promastigotes ( $IC_{50}$ ) (Comandolli-Wyrepkowki *et al.* 2017).

### Biological tests in amastigote forms

The evaluation of *in vitro* antileishmanial activity of the copper(I) complex in amastigotes was performed as described by Nascimento *et al.* (2019), with some adaptations. Murine peritoneal macrophages and human monocytes (individual assays) were infected with promastigotes of each of the *Leishmania* species in a 10:1 ratio ( $10^6$  parasites:  $10^5$  cells) on glass coverslips in 24-well plates containing complete RPMI culture medium, which was subsequently placed in an incubator at 37 °C and 5%  $CO_2$  for up to 2 h. After this time, the infected cells were maintained either in complete RPMI medium (control) or RPMI medium containing different concentrations of the copper(I) complex (0.16, 0.08, 0.04 and 0.02 mM) and Glucantime® (33.00, 16.50, 8.25, 4.12 and 2.06 mM) for 24, 48 and 72 h at 37 °C and 5%  $CO_2$ . Then, the coverslips were fixed and stained every 24 h using the Quick Panoptic method (Laborclin®, Brazil) and analyzed using optical microscopy. The percentage of infected cells was estimated by randomly counting 100 infected and uninfected cells on each slide (Comandolli-Wyrepkowki *et al.* 2017).

### Preparation of topical formulation for *in vivo* biological assays

The ointment was prepared with 0.02% butyl hydroxytoluene, propylene glycol, 30% anhydrous lanolin and solid petroleum jelly. Then, 0.5 mg of copper(I) complex in 80 mg ointment was added. Base ointment without copper(I) complex was used as a placebo control.

### *In vivo* biological assay

Ninety male golden hamsters (*Mesocricetus auratus*), weighing 120 g and aged 60 days, were kept in the Central Animal Facility at INPA, with water and food *ad libitum*, in rooms with controlled photoperiod and temperature (22–24 °C). The ninety animals were divided into three groups of thirty animals for the experimental infection procedure. From each group of 30 animals, 24 were infected by one of the species of *Leishmania* studied, and the other six animals were not infected and constituted the control group. In the hamster's snout,  $0.1\text{ mL}^{-1}$  of sterile saline (0.9%) containing promastigotes ( $10^6$  promastigotes  $\text{mL}^{-1}$ ) in stationary phase was injected intradermally. After the lesion appeared, at variable times, according to the species of *Leishmania*, the animals were randomly divided into five groups (six animals

per group) and treated once daily, for 25 to 30 days, in the following manner: I) uninfected and untreated; II) infected and untreated; III) infected and treated with base ointment (placebo); IV) infected and treated with Glucantime® 20 mg( $Sb^5$ )  $\text{kg day}^{-1}$  intramuscularly; V) infected and treated with ointment containing 0.5 mg of the copper(I) complex. We did not perform *in vivo* tests with *L. (V.) naiffi* due to the lack of macroscopically visible skin lesions in the hamsters.

To evaluate the treatments, the total lesion volume was determined on a weekly basis by measuring the snout with a digital caliper (MTX), the lesions were photo-documented (SM-G570M/DS, Samsung, South Korea) for morphological analysis (Comandolli-Wyrepkowki *et al.* 2017) and the animals were weighed.

### Parasitological and hematological evaluation of treatment

All animals used in the experiment were euthanized through intramuscular injection of ketamine ( $10\text{ mg kg}^{-1}$ ) and xylazine ( $90\text{ mg kg}^{-1}$ ). After the euthanasia procedure, the liver, spleen and kidneys were removed and weighed on a precision scale. Skin tissue fragments from the inoculated site, as well as viscera tissue (liver, spleen and kidneys), were excised aseptically and cultured in Novy-MacNeal-Nicolle (NNN) medium for up to 20 days at 25 °C. The result was considered positive when at least one form of the parasite was isolated from the culture medium (Comandolli-Wyrepkowki *et al.* 2017).

Tissue samples from the lesion area on the snout of each animal were imprinted on glass slides. These were fixed and stained using the Quick Panoptic method and analyzed under optical microscopy. The percentage of infected cells was estimated by randomly counting 25 fields in each coverslip (Comandolli-Wyrepkowki *et al.* 2017).

Blood smears were prepared on slides and, subsequently, the biological material was fixed and stained using the Quick Panoptic method. The leukocyte cells were differentiated and quantified by counting 100 cells per slide at 400x magnification.

### Statistical analysis

$IC_{50}$  and  $CC_{50}$  were obtained through linear regression using the number of living cells. A one-way ANOVA followed by Tukey's test was used to assess the significance of the differences between the groups of the *in vivo* biological assay, at the 5% significance level. All statistical analyses were performed using the GraphPad Prism program version 6.0 for Windows (GraphPad Software, San Diego, CA).

### Ethical aspects

The *in vitro* tests were approved by the Ethics Committee on the Use of Animals of INPA (CEUA/INPA authorization # 023/2020 - 01280.000455/2020-41) and by the Research

Ethics Committee of Universidade Federal do Amazonas (CAAE authorization # 29406319.2.0000.5020). The *in vivo* tests were approved by the Ethics Committee on the Use of Animals of INPA (CEUA/INPA authorization # 059/2018 – 01280.001884/2018-11).


## RESULTS

In the cytotoxicity evaluation, the copper(I) complex showed moderate toxicity for murine peritoneal macrophages and human monocytes, with cell viability above 80% and 75%, respectively. The  $CC_{50}$  of the copper(I) complex for both cell types was > 0.4 mM during the incubation period. Cell viability was 80% in the group treated with Glucantime®, and

85% in the group treated with dimethyl sulfoxide (DMSO), and 86% and 93% in murine peritoneal macrophages and human monocytes, respectively.

The *in vitro* experiments carried out with promastigotes incubated during 24, 48 and 72 h, the copper(I) complex showed a lower  $IC_{50}$  in *L. (V.) braziliensis* promastigotes in 72 h (0.071 mM), followed by *L. (V.) guyanensis* in 48 h (0.086 mM), *L. (V.) naiffi* in 72 h (0.096 mM) and *L. (L.) amazonensis* in 72 h (0.186 mM) and  $SI > 20$  in 72 h for all the tested species (Table 1).

There was no significant difference in the parasitic viability of *L. (L.) amazonensis* promastigotes (Figure 1a), however, the concentrations of 0.16 and 0.08 mM of the copper(I) complex



**Figure 1.** Parasitic viability of promastigote forms of *Leishmania (L.) amazonensis* (A); *L. (V.) guyanensis* (B); *L. (V.) braziliensis* (C); and *L. (V.) naiffi* (D). Untreated promastigotes (black columns), promastigotes treated with 33 mM Glucantime® (white columns) and 0.16, 0.08, 0.04, 0.02 and 0.01 mM copper(I) complex (dotted columns). Columns represent the mean and bars the standard deviation. Different letters within periods indicate significant difference according to the Tukey test ( $p < 0.05$ ).

**Table 1.** Inhibitory concentration at 50% ( $IC_{50}$  mM  $\pm$  SD) and selectivity index (SI) of [HB(pz)<sub>3</sub>]Cu(PCN) and Glucantime® in promastigote forms of *Leishmania* spp.

Species	Period (h)	[HB(pz) <sub>3</sub> ]Cu(PCN)		Glucantime®	
		$IC_{50}$ (mM)	SI	$IC_{50}$ (mM)	SI
<i>L. (L.) amazonensis</i>	24	0.216 $\pm$ 0.14	2.20	38.15 $\pm$ 0.15	10.32
	48	0.213 $\pm$ 0.25	3.71	26.13 $\pm$ 0.33	37.42
	72	0.186 $\pm$ 0.40	20.64	18.08 $\pm$ 0.21	85.45
<i>L. (V.) guyanensis</i>	24	0.300 $\pm$ 0.10	1.59	46.28 $\pm$ 0.09	8.51
	48	0.086 $\pm$ 0.23	0.08	93.12 $\pm$ 0.08	10.50
	72	0.117 $\pm$ 0.20	34.90	42.8 $\pm$ 0.47	36.10
<i>L. (V.) braziliensis</i>	24	0.094 $\pm$ 0.50	5.07	46.23 $\pm$ 0.42	8.52
	48	0.078 $\pm$ 0.83	9.71	31.34 $\pm$ 0.62	31.19
	72	0.071 $\pm$ 1.03	54.08	17.24 $\pm$ 0.68	89.62
<i>L. (V.) naiffi</i>	24	0.173 $\pm$ 0.19	2.75	40.71 $\pm$ 0.22	9.67
	48	<0.01 $\pm$ 0.53	75.8	25.96 $\pm$ 0.17	37.66
	72	0.096 $\pm$ 0.29	40	24.26 $\pm$ 0.36	63.68

induced a significant decrease in parasitic viability in *L. (V.) guyanensis* ( $F = 129.9$ ,  $p < 0.0001$ ) and *L. (V.) naiffi* ( $F = 174.1$ ,  $p < 0.0001$ ) relative to the negative control, with a reduction  $> 50\%$  in 48 and 72 h (Figure 1b,d). In *L. (V.) braziliensis*, this reduction is observed throughout the incubation period, with significant differences from the negative control ( $F = 162.1$ ,  $p < 0.0001$ ). The copper(I) complex showed efficacy similar to Glucantime® and a concentration-dependent effect for all species (Figure 1c).


In the *in vitro* experiments with amastigotes incubated, the copper(I) complex showed promising results against *L. (V.) braziliensis* and *L. (L.) amazonensis* over 72 h ( $IC_{50} < 0.02$  mM) and *L. (V.) guyanensis* over 24 h ( $IC_{50} < 0.081$  mM) in

both cell models. For *L. (V.) naiffi*, the tested concentrations were not effective in inhibiting amastigote forms ( $IC_{50} > 0.16$  mM) (Table 2).

As observed in the promastigote forms, the copper(I) complex was more effective against *L. (V.) braziliensis*, and induced a 75% reduction in the infection rate of murine peritoneal macrophages ( $F = 303.1$ ,  $p < 0.0001$ ) over the entire period of incubation. There was no significant difference from cells treated with Glucantime® (Figure 2c). Similar results were observed for *L. (L.) amazonensis*, but only after 48 and 72 h (Figure 2a). In contrast, in *L. (V.) guyanensis* there was a significant reduction ( $F = 53.2$ ,  $p < 0.0001$ ) in the number of infected murine peritoneal macrophages only at 24 h (Figure

**Table 2.** Inhibitory concentration ( $IC_{50}$  mM  $\pm$  SD) of the complex  $[HB(pz)_3]Cu(PCN)$  and Glucantime® in amastigotes of *Leishmania* spp. in murine peritoneal macrophages and human monocytes. SD = standard deviation.

Species	Period (h)	$[HB(pz)_3]Cu(PCN)$		Glucantime®	
		Macrophages	Monocytes	Macrophages	Monocytes
<i>L. (L.) amazonensis</i>	24	0.321 $\pm$ 4.24	> 0.16	12.40 $\pm$ 3.00	8.73 $\pm$ 5.65
	48	< 0.02	0.107 $\pm$ 7.07	< 4 $\pm$ 3.00	75.75 $\pm$ 5.65
	72	< 0.02	0.355 $\pm$ 4.41	2.09 $\pm$ 2.47	224 $\pm$ 3.71
<i>L. (V.) guyanensis</i>	24	0.081 $\pm$ 4.06	< 0.2	21.51 $\pm$ 2.65	2.07 $\pm$ 3.61
	48	0.77 $\pm$ 1.94	0.43 $\pm$ 5.74	36.66 $\pm$ 5.12	147.87 $\pm$ 5.65
	72	21.24 $\pm$ 1.94	0.2	78.54 $\pm$ 3.18	244.39 $\pm$ 2.48
<i>L. (V.) braziliensis</i>	24	< 0.02	0.40 $\pm$ 4.59	4.35 $\pm$ 7.24	330.63 $\pm$ 7.77
	48	< 0.02	0.94 $\pm$ 4.24	< 4	< 4
	72	< 0.02	< 0.02 $\pm$ 3.42	< 4	< 4
<i>L. (V.) naiffi</i>	24	0.31 $\pm$ 3.53	1.45 $\pm$ 2.12	> 100 $\pm$ 3.53	81.99 $\pm$ 4.66
	48	0.29 $\pm$ 5.30	3.84 $\pm$ 0.96	> 100 $\pm$ 3.53	> 100 $\pm$ 1.23
	72	0.21 $\pm$ 2.12	5.1 $\pm$ 0.86	52.18 $\pm$ 5.65	>100 $\pm$ 0.97



**Figure 2.** Infectivity rate of murine peritoneal macrophages infected by *Leishmania* (*L. amazonensis* (A); *L. (V.) guyanensis* (B); *L. (V.) braziliensis* (C); and *L. (V.) naiffi* (D). Untreated murine peritoneal macrophages (black columns), murine peritoneal macrophages treated with 33 mM Glucantime® (white columns) and 0.16, 0.08, 0.04 and 0.02 mM copper(I) complex (dotted columns). Columns represent the mean and bars the standard deviation. Different letters within periods indicate significant differences according to the Tukey test ( $p < 0.05$ ).

2b) and in *L. (V.) naiffi* the significant reduction occurred at 24 and 72 h ( $F = 53.2$ ,  $p < 0.0001$ ) (Figure 2d). It is noteworthy that the inhibition of infectivity was not observed in human monocytes, as all groups had a high rate of monocyte infection by *Leishmania* spp.

In the experimental treatment of hamsters, the animals infected with *L. (L.) amazonensis* and left untreated had a higher average weight (173.33 g) than the average weight in the other groups (150.16 g) ( $p < 0.0001$ ). In hamsters infected with *L. (V.) braziliensis*, the group treated with Glucantime® (average 197.33 g) had a higher weight than in the other groups (average 173.45 g) ( $p < 0.0001$ ). In the groups infected with *L. (V.) guyanensis*, there was no difference among groups in the weight of the animals.


Regarding the clinical evolution of leishmaniasis, there was no significant difference in the volume of the snout among hamster groups infected with *L. (L.) amazonensis* (Figure 3a). The treatment lasted only 25 days due to the lethargic behavior of the animals and the exacerbated evolution of the lesions.

Animals infected with *L. (V.) guyanensis* and *L. (V.) braziliensis* and treated with the copper(I) complex ointment showed a reduction of only 17% and 18% in the volume of the snout, respectively, by the end of the 30-day period. There was no significant difference among infected and untreated animals. In the Glucantime® group, the volume of the snout was reduced by 73% ( $F = 75.03$ ,  $p < 0.0001$ ) in *L. (V.) guyanensis* and 70% ( $F = 11.96$ ,  $p < 0.0001$ ) in *L. (V.) braziliensis*, differing from the other treatment groups (Figure 3b,c).

For all *Leishmania* species, the treatment with either Glucantime® or with the copper(I) complex ointment induced a reduction in the volume of the snout after the 15<sup>th</sup> day of treatment. In all groups infected with *L. (L.) amazonensis*, until the second week of treatment, a gradual increase in the volume of the snout was observed due to the formation of the nodule and edema. After the 15<sup>th</sup> day, there was a reduction in edema and the beginning of ulceration of the lesions, and the snout volume was larger during the entire experimental period when compared to the groups infected by other species, with ulcerated, exacerbated lesions and the presence of scabs. None of the groups presented clinical cure under any type of treatment (Figure 4a).

All groups infected by *L. (V.) guyanensis* (Figure 4b) and *L. (V.) braziliensis* (Figure 4c) presented nodule formation, but no exacerbated ulceration lesion. The most frequent lesions had scabs. The Glucantime® groups achieved 100% clinical cure at the end of the 30 days of treatment. In the groups treated with copper(I) complex ointment, only 50% of the animals showed clinical cure with wound healing, but all animals presented snout edema until the 30<sup>th</sup> day of treatment.


NNN cultures revealed the presence of viable flagellate parasites in the lesion skin and in liver samples in all treatments



**Figure 3.** Evolution of the snout volume of hamsters infected with *Leishmania* (*L. (L.) amazonensis* (A); *L. (V.) guyanensis* (B); and *L. (V.) braziliensis* (C). Uninfected and untreated hamsters (circles), infected and untreated (squares), infected and treated with placebo (triangles), infected and treated intramuscularly with Glucantime® 20 mgSb<sup>5</sup> kg day<sup>-1</sup> (diamonds) and infected and treated with ointment containing 0.5 mg of copper(I) complex (X-mark).

with all *Leishmania* species. There was no significant difference in the infectivity rate among treatments in animals infected with *L. (L.) amazonensis*. The animals infected with *L. (V.) guyanensis* and *L. (V.) braziliensis* presented a lower infection rate in the Glucantime® treatment when compared to the other treatments ( $F = 33.98$ ,  $p = 0.0006$  and  $F = 67.98$ ,  $p = 0.0013$ , respectively) (Figure 5).

There was no significant difference in organ weight (liver, spleen and kidney) and hematological parameters among the experimental groups for any of the tested *Leishmania* species.




**Figure 4.** Clinical aspects of the snout lesions of hamsters, *Mesocricetus auratus* infected by *Leishmania (L.) amazonensis* (A) on the 25<sup>th</sup> day of treatment; *L. (V.) guyanensis* (B) and *L. (V.) braziliensis* (C) on the 30<sup>th</sup> day of treatment. A1, B1, C1 – uninfected and untreated animals; A2, B2, C2 – infected and untreated animals; A3, B3, C3 – animals infected and treated with Glucantime<sup>®</sup> (20 mgSb<sup>5</sup> kg day<sup>-1</sup> intramuscularly); A4, B4, C4 – animals infected and treated with placebo; A5, B5, C5 – animals infected and treated with ointment containing 0.5 mg of copper(I) complex. This figure is in color in the electronic version.

## DISCUSSION

As expected, in the biological cytotoxicity assays, the copper(I) complex showed moderate cytotoxicity and cell viability (> 75%, CC<sub>50</sub> > 0.4 mM), similar to that observed in the treatment with Glucantime<sup>®</sup>. Similar results were obtained for different copper(II) complexes, with IC<sub>50</sub> values of 186.61 μM (Boutaleb-Charki *et al.* 2009), 558.6 μM (Caballero *et al.* 2014) and 813.5 μM in cells of the J774 lineage (Méndez-Arriaga *et al.* 2020).

In our tests of antileishmanial activity *in vitro*, a dose-dependent response was observed, in which the highest concentrations of the copper(I) complex (0.16 and 0.08 mM) were more effective in inhibiting promastigotes and amastigotes. Similar dose-dependent parasitic inhibition (0.365 mg mL<sup>-1</sup>) was reported by Hummadi *et al.* (2005). In the promastigote forms of *L. (L.) amazonensis*, there was no parasitic inhibition, however, the copper(I) complex was more efficient against amastigotes of this species, with a 75% reduction in the infection rate at 48 and 72 h. Likewise, Maffei *et al.* (2009) observed a IC<sub>50</sub> decline (at 48 and 72 hours)



**Figure 5.** Infection rate via quantification of infected macrophages on the slide print of fragments of lesions from hamsters infected with *Leishmania (L.) amazonensis* (A); *L. (V.) guyanensis* (B); and *L. (V.) braziliensis* (C). Infected and untreated animals (black columns), animals infected and treated with 20 mgSb<sup>5</sup> kg day<sup>-1</sup> of Glucantime<sup>®</sup> (white columns), animals infected and treated with placebo (striped columns), and animals infected and treated with ointment containing 0.5 mg of copper(I) complex (dotted columns). Columns represent the mean and bars the standard deviation. Different letters indicate significant differences according to the Tukey test ( $p < 0.05$ ).

for three copper(II) complexes against *L. (L.) amazonensis*, suggesting a long-term activity for this species.

In the promastigote forms of *L. (V.) braziliensis*, the copper(I) complex inhibited more than 50% of the promastigote forms, with SI greater than 20 after 72 h and greater efficacy than Glucantime<sup>®</sup>, while in the amastigote forms, the copper(I) complex decreased the infection rate by at least 75%, with similar efficacy to Glucantime<sup>®</sup>. These results corroborate those of Caballero *et al.* (2014), who showed that copper(II) complexes had similar toxicity to Glucantime<sup>®</sup> in the promastigote and amastigote forms of *L. (V.) braziliensis*,

and a SI higher than 54.2 after 72 h. Other studies, such as those of Méndez-Arriaga *et al.* (2018) and Méndez-Arriaga *et al.* (2020), also reported the activity of copper(II) complexes in *L. (V.) braziliensis*, with IC<sub>50</sub> of 100.2 µM (IS 14.5) and 42.6 µM (IS 19.1), respectively.

To the best of our knowledge, there are no published studies on the antileishmanial activity of metal complexes for *L. (V.) guyanensis* and *L. (V.) naiffi*. Our results indicate that the copper(I) complex is efficacious against promastigote forms of these species. This is also the first report of the antileishmanial effects of a copper complex in a preclinical study with animals.

Currently there is no information available in the literature regarding the topical experimental treatment of leishmaniasis with metal complexes. The drugs currently used to treat cutaneous leishmaniasis are administered parenterally and have serious adverse effects. In this sense, topical administration of medications for leishmaniasis may be an interesting option, since the use of topical medications allows the concentration of the active ingredient in the site of infection. It offers a possible decrease in toxicity and, because it is not invasive, the treatment can be done outside the hospital environment (Bocxlaer *et al.* 2018). In addition, topical treatment can also be used together with other drugs, thus potentiating and reducing the time of treatment of the disease. Due to the lipophilic characteristics of the copper(I) complex, the use of hydrophobic ointments is an attractive alternative, since they have an emollient effect, are difficult to remove, do not become dry and, in addition, allow the drug to remain in prolonged contact with the skin and act as an occlusive dressing (Otto *et al.* 2018).

Another relevant factor for the development of a topical formulation is related to intoxication by metals because, although copper is an essential element for several physiological and biochemical functions, it is also related to diseases caused by the abundance and deficiency of this metal in the body. As such, it is necessary to stipulate doses for treatment that take into consideration the essential daily concentrations. In an adult man, these can vary from 0.9 to 2.2 mg (Baierle *et al.* 2010), although its topical use has a different effect in terms of absorption by the body, differently than if it were administered parenterally.

None of our treatments with the copper(I) complex achieved the clinical cure (total healing and reepithelization of the skin) and parasitological cure (the complete elimination of the parasite) of the animals infected with *L. (L.) amazonensis*. In animals infected with *L. (V.) guyanensis* and *L. (V.) braziliensis*, the copper(I) complex ointment induced a reduction in lesion volume, but clinical cure was achieved only in 50% of the infected animals, and no parasitological cure was observed. In contrast, animals treated with Glucantime® achieved 100% clinical cure, but also no parasitological cure,

which had already been demonstrated in humans (Martínez-Valencia *et al.* 2017).

Although several *in vitro* studies with metal complexes have been developed in the search for new alternative treatments for cutaneous leishmaniasis, few have evaluated the effects *in vivo*. Among them, the study by Nascimento *et al.* (2019) suggested a promising leishmanicidal effect of the ruthenium nitrosil complex (300 µg kg day<sup>-1</sup> through oral administration) against *L. (V.) braziliensis* in a model of skin infection *in vivo* (hamster), obtaining a 51% reduction in lesion size and 99.9% elimination of parasites. These authors did not observe toxic reactions to the metal complex, nor changes in size, weight and appearance of organs, or in the leukogram of test animals, which is corroborates in our study.

Our results encourage further studies that evaluate the effectiveness of the copper(I) complex in a new formulation and a new experimental treatment scheme, with emphasis on the effectiveness of the skin permeation issue, animal experimentation model, species of *Leishmania* involved, concentrations of the active principle and treatment time. Further research is recommended using different concentrations, formulations, routes of administration, and treatment time using the copper(I) complex, and it is also necessary to elucidate the therapeutic mechanism and the toxicological aspects.

## CONCLUSIONS

The copper(I) complex showed promising *in vitro* activity against the evolutionary forms of *Leishmania (V.) braziliensis*. In the pre-clinical study, there was a reduction of about 17% and 18% in the size of skin lesions in animals infected with parasites of the sub-genus *Viannia*, species *L. (V.) guyanensis* and *L. (V.) braziliensis* respectively, treated topically with the ointment containing the copper(I) complex. It is suggested that the ointment be used in conjunction with other drugs for parasitic infections by the subgenus *Viannia*.

## ACKNOWLEDGMENTS

The authors would like to thank Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES, PhD. Francesco Tisato, MSc. Maricleide de Farias Naiff and technician Lorival Maciel Castro.

## REFERENCES

- Arndt, A.; Liria, C.W.; Yokoyama-Yasunaka, J.K.U.; Manchini, M.T.; Uliana, S.R.B.; Espósito, B.P. 2017. New iminodibenzyl derivatives with anti-leishmanial activity. *Journal of Inorganic Biochemistry*, 172: 9–15.
- Baierle, M.; Valentini, J.; Paniz, C.; Moro, A.; Barbosa Junior, F.; Garcia, S.J. 2010. Possíveis efeitos do cobre sanguíneo sobre parâmetros hematológicos em idosos. *Jornal Brasileiro de Patologia e Medicina Laboratorial*, 46: 463–479.



- Bastos, M.M.; Boechat, N.; Hoelz, L.V.B.; Oliveira, A.P. 2016. Quimioterapia antileishmaniana: Uma revisão bibliográfica. *Revista Virtual de Química*, 6: 2072-2104.
- Blanco, V.R.; Nascimento-Júnior, N.M. 2017. Leishmaniose: Aspectos gerais relacionados com a doença, o ciclo do parasita, fármacos disponíveis, novos protótipos e vacinas. 2017. *Revista Virtual de Química*, 9: 861-876.
- Bocxlaer, K.V.; Gaukel, E.; Hauser, D.; Park, S.H.; Schock, S.; Yardley, V.; *et al.* 2018. Topical treatment for cutaneous leishmaniasis: Dermatopharmacokinetic lead optimization of benzoxaboroles. *Antimicrobial Agents and Chemotherapy*, 62:e02419-17.
- Boutaleb-Charki, S.; Marín, C.; Maldonado, C.R.; Rosales, M.J.; Urbano, J.; Guitierrez-Sánchez, R.; Quirós, M.; Salas, J.M.; Sánchez-Moreno, M. 2009. Copper(II) complexes effects potential anti-parasitic agents. *Drug Metabolism Letters*, 3: 35-44.
- Brasil. 2017. *Manual de Vigilância da Leishmaniose Tegumentar Americana*. Ministério da Saúde, Secretaria de Vigilância em Saúde, Brasília, 189p. ([https://bvsm.s.saude.gov.br/bvs/publicacoes/manual\\_vigilancia\\_leishmaniose\\_tegumentar.pdf](https://bvsm.s.saude.gov.br/bvs/publicacoes/manual_vigilancia_leishmaniose_tegumentar.pdf)). Accessed on 30 Jun 2021.
- Bruschi, F.; Gradoni, L. 2018. *The Leishmaniasis: Old Neglected Tropical Diseases*, 1st ed. Springer International Publishing, New York, 245p.
- Caballero, A.B.; Rodríguez-Diéguez, A.; Quirós, M.; Salas, J.M.; Huerta, O.; Ramírez-Macías, I.; *et al.* 2014. Triazolopyrimidine compounds containing first-row transition metals and their activity against the neglected infectious Chagas disease and leishmaniasis. *European Journal of Medicinal Chemistry*, 85: 526-534.
- Comandolli-Wyrepkowski, C.D.; Jensen, B.B.; Grafova, I.; Santos, P.A.; Barros, A.M.C.; Soares, F.V.; Barcellos, J.F.M.; Silva, A.L.; Grafov, A.; Franco, A.M.R. 2017. Antileishmanial activity of extracts from *Libidibia ferrea*: development of *in vitro* and *in vivo* tests. *Acta Amazonica*, 47: 331-340.
- Gandin, V.; Tisato, F.; Dolmella, A.; Santini, M.P.; Santini, C.; Giorgetti, M.; Marzano, C.; Porchia, M. 2014. *In vitro* and *in vivo* anticancer activity of copper(I) complexes with homoscorpionate tridentate tris(pyrazolyl)borate and auxiliary monodentate phosphine ligands. *Journal of Medicinal Chemistry*, 57: 4745-4760.
- Hummadi, Y.M.A.L.; Najim, R.A.; Al-Bashi, N. 2005 *Leishmania major* and *Leishmania tropica*: I the *in vitro* effects of an immunomodulator, S2-Complex. *Experimental Parasitology*, 111: 47-54.
- Hussain, A.; Alajmi, M.F.; Rehman, M.T.; Amir, S.; Hussain, F.M.; Alsalmeh, A.; Siddiqui, M.A.; Alkhedhairi, A.A.; Khan, R.A. 2019. Copper(II) complexes as potential anticancer and nonsteroidal anti-inflammatory agents: *In vitro* and *in vivo* studies. *Scientific Reports*, 9: 1-17. doi.org/10.1038/s41598-019-41063-x.
- Keighobadi, M.; Akhtari, J.; Fakhar, M.; Emami, S.; Mirzaei, H. 2018. An overview on anticancer drugs with antileishmanial activity. *Journal of Mazandaran University of Medical Sciences*, 28: 154-165.
- Krupanidhi, S.; Sreekumar, A.; Sanjeevi, C.B. 2008. Copper & biological health. *Indian Journal of Medical Research*, 128: 448-461.
- Maffei, R.S.; Yokoyama-Yasunaka, J.K.U.; Miguel, D.C.; Uliana, S.R.B.; Espósito, B.P. 2009. Synthesis, characterization and evaluation of antileishmanial activity of copper(II) with fluorinated  $\alpha$ -hydroxycarboxylate ligands. *Biometals*, 22: 1095-1101.
- Martínez-Valencia, A.J.; Daza-Rivera, C.F.; Rosales-Chimala, M.; Cossio, A.; Ricón, E.J.C.; Desai, M.M.; Saraiva, G.N.; Gómez, M.A. 2017. Clinical and parasitological factors in parasite persistence after treatment and clinical cure of cutaneous leishmaniasis. *Plos Neglected Tropical Disease*, 11: e0005713.
- Méndez-Arriaga, J.M.; Oyarzabal, I.; Escolano, G.; Rodríguez-Diéguez, A.; Sánchez-Moreno, M.; Salas, J.M. 2018. *In vitro* leishmanicidal and trypanocidal evaluation and magnetic properties of 7-amino-1,2,4-triazolo[1,5-a]pyrimidine Cu(II) complexes. *Journal of Inorganic Biochemistry*, 180: 26-32.
- Méndez-Arriaga, J.M.; Rodríguez-Diéguez, A.; Sánchez-Moreno, M. 2020. *In vitro* leishmanicidal activity of copper(II) 5,7-dimethyl-1,2,4-triazolo[1,2,4]Triazolo [1,5-a]Pyrimidine Derivatives as [1,5-a]pyrimidine complex and analogous transition metal series. *Polyhedron*, 176: 1-6. doi.org/10.1016/j.poly.2019.114272.
- Nascimento, N.R.F.; De Aguiar, F.L.N.; Santos, C.F.; Luna Costa, A.M.; De Jesus Haridoim, D.; Da Silva Calabrese, K.; Gadelha Rocha, M.F. 2019. *In vitro* and *in vivo* leishmanicidal activity of a ruthenium nitrosyl complex against *Leishmania (Viannia) braziliensis*. *Acta Tropica*, 196: 61-65.
- Navarro, M.; Cisneros-Fajardo, E.J.; Fernandez-Mestre, M.; Arrieché, D.; Marchan, E. 2003. Synthesis, characterization, DNA binding study and biological activity against. *Journal of Inorganic Biochemistry*, 97: 364-369.
- Ong, Y.C.; Roy, S.; Andrews, P.C.; Gasser, G. 2019. Metal compounds against neglected tropical diseases. *Chemical Reviews*, 119: 730-796.
- Otto, V.; França, F.; Horfler, R. 2018. Formas farmacêuticas semissólidas para tratamento tópico. *Fármaco Terapêutica*, 2: 3-9.
- Porchia, M.; Tisato, F.; Zancato, M.; Gandin, V.; Marzano, C. 2020 *In vitro* antitumor activity of water-soluble copper(I) complexes with diimine and monodentate phosphine ligands. *Arabian Journal of Chemistry*, 13: 998-1010.
- Portas, A.S.; Miguel, D.C.; Yokoyama-Yasunaka, J.K.U.; Uliana, S.R.B.; Espósito, B.P. 2012. Increasing the activity of copper(II) complexes against *Leishmania* through lipophilicity and pro-oxidant ability. *Journal of Biological Inorganic Chemistry*, 17: 107-112.
- Saeed, A.; Larik, F.A.; Jabeen, F.; Mehfooz, H.; Ghumro, S.A.; El-Seedi, H.R.; Ali, M.; Channar, P.A.; Ashraf, H. 2018. Synthesis, antibacterial and antileishmanial activity, cytotoxicity, and molecular docking of new heteroleptic copper(I) complexes with thiourea ligands and triphenylphosphine. *Russian Journal of General Chemistry*, 88: 541-550.
- Tapanelli, S.; Habluetzel, A.; Pellei, M.; Marchiò, L.; Tombesi, A.; Cappare, A.; Santini, C. 2017. Novel metalloantimalarials: Transmission blocking effects of water soluble Cu(I), Ag(I) and Au(I) phosphane complexes on the murine malaria parasite

*Plasmodium berghei*. *Journal of Inorganic Biochemistry*, 166: 1–4.  
doi.org/10.1016/j.jinorgbio.2016.10.004.

Teles, C.B.G.; Santos, A.P.A.; Freitas, R.A.; Oliveira, A.F.J.; Ogawa, G.M.; Rodrigues, M.S.; Pessoa, F.A.C.; Medeiros, J.F.; Camargo, L.M.A. 2016. Phlebotomine sandfly (Diptera: Phlebotomidae) diversity and their *Leishmania* DNA in a hot spot of American Cutaneous Leishmaniasis human cases along the Brazilian with Peru and Bolivia. *Memórias do Instituto Oswaldo Cruz*, 111: 423–432.

Tisato, F.; Marzano, C.; Peruzzo, V.; Tegoni, M.; Giorgetti, M.; Damjanovic, M.; Trapananti, A.; Bagno, A.; Santini, C.; Pelli, M.; *et al.* 2016. Insights into the cytotoxic activity of the phosphane copper(I) complex [Cu(thp)<sub>4</sub>][PF<sub>6</sub>]. *Journal of Inorganic Biochemistry*, 165: 80–91.

WHO. 2021. World Health Organization. Leishmaniasis. ([https://www.who.int/health-topics/leishmaniasis#tab=tab\\_1](https://www.who.int/health-topics/leishmaniasis#tab=tab_1)). Accessed on 22 Feb 2021.

**RECEIVED:** 22/03/2021

**ACCEPTED:** 19/06/2021

**ASSOCIATE EDITOR:** Waldireny C. Rocha



This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.